CBP-1018

N/A

Report date: 2025/03/31 11:05:14
NME

Base Information

Drug NameCBP-1018
Drug Alias NameCBP-1018
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionAnti-PSMAAnti-FOLR1Tubulin polymerisation inhibitors
TargetsProstate-Specific Membrane AntigenFolate receptor alphaTubulin
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsLung Neoplasms +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsLung Neoplasms
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A